MILFORD, Mass., USA — Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), leaders in the contract development and manufacturing of oligonucleotides, today announced the appointment of Tammy Cooper as President, effective June 21, 2024. Cooper, who currently serves as Vice President of Business Development and Project Management, will succeed Seiji Fujioka and report to Yoshihiko Terada, the incoming Executive Chairman.
Leadership Transition to Drive Future Growth
Tammy Cooper’s elevation to President marks a significant milestone in her 19-year tenure at Nitto Avecia, reflecting her pivotal role in the company’s expansion during its recent rapid growth phase. “I am deeply honored to serve as the first female president of Nitto Avecia. I am inspired by the limitless possibilities ahead for our company and the dedication, resilience, and commitment of our employees. Through our culture of innovation, we will continue to bring the development and manufacturing of oligonucleotides to new heights of success,” said Ms. Cooper.
Yoshihiko Terada, who brings extensive experience from both the pharmaceutical and management consulting industries, will transition from his role as Chief of Staff and Corporate Vice President at Nitto Denko to Executive Chairman of Nitto Avecia.
“There is an extremely positive outlook for the oligonucleotide market with great opportunities for Nitto Avecia, and Nitto Avecia Pharma Services to partner with our customers on life-changing and life-saving pharmaceuticals. I look forward to continuing to work with this exceptional team as we contribute to patients and the oligonucleotide market,” Terada stated.
About Nitto Denko Avecia Inc.
Nitto Denko Avecia Inc. is a premier provider in the development and manufacturing of oligonucleotide therapeutics, boasting facilities in Milford, MA, and Cincinnati, OH, along with Nitto Avecia Pharma Services in Irvine, CA. The company has a rich history of manufacturing over 1,200 oligonucleotide sequences and has a robust late-phase portfolio. As the first CDMO to offer end-to-end solutions for oligonucleotide therapeutics, Nitto Avecia continues to be at the forefront of this rapidly evolving field.
About Nitto Denko Corporation
Established in 1918, Nitto is a leading materials manufacturer in Japan, specializing in a diverse range of products across electronics, automobiles, ecology, and life sciences. With a commitment to innovation centered around customer needs, Nitto Denko aims to inspire and amaze as a top ESG company under its brand slogan “Innovation for Customers.”
Also Read : Ulric Neisser’s Legacy: Shaping Cognitive Psychology and Transforming HR Practices
